DNLI Denali Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1714899 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY37.0%
TTM EPS YoY41.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.9%
ROA-27.2%
ROIC (approx.)-50.8%
Asset turnover—
Leverage & solvency
Liabilities / assets26.2%
Debt / equity0.00x
Current ratio6.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.41x
Accruals ratio11.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $17.78M | $3.60M | — | $0 | $0 | $0 | — | $0 |
| Cost of revenue | $192,000 | $93,000 | — | — | $0 | $0 | — | — |
| Gross profit | $17.59M | $3.51M | — | — | $0 | $0 | — | — |
| R&D expense | $106.10M | $97.02M | $103.85M | $97.91M | $101.95M | $102.70M | $116.23M | $99.79M |
| SG&A expense | $37.48M | $36.28M | $33.51M | $39.46M | $35.48M | $32.27M | $29.35M | $30.06M |
| Operating income | -$126.75M | -$130.54M | -$137.36M | -$137.37M | -$137.43M | -$134.96M | -$145.58M | -$129.85M |
| Net income | $70.13M | -$127.55M | -$128.45M | -$128.55M | -$126.90M | -$124.12M | -$132.97M | -$114.75M |
| EBITDA | -$123.18M | -$126.97M | -$134.51M | -$134.50M | -$134.49M | -$131.92M | -$143.25M | -$127.99M |
| EPS (basic) | 0.37 | -0.68 | -0.69 | — | -0.74 | -0.72 | -0.78 | — |
| EPS (diluted) | 0.37 | -0.68 | -0.69 | — | -0.74 | -0.72 | -0.78 | — |
| Weighted avg. shares (diluted) | 192.08M | 187.31M | 186.64M | — | 172.42M | 171.45M | 171.22M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $102.87M | $201.53M | $387.63M | $205.33M | $94.07M | $144.31M | $60.05M | $176.53M |
| Short-term investments | $413.33M | $508.94M | $600.06M | $662.55M | $757.24M | $757.75M | $760.98M | $657.37M |
| Receivables | $18.88M | $3.93M | — | $0 | — | — | — | — |
| Inventory | $26.27M | $4.14M | — | $0 | — | — | — | — |
| Current assets | $591.71M | $753.93M | $1.02B | $900.66M | $882.60M | $934.71M | $878.64M | $864.44M |
| PP&E, net | $47.91M | $49.93M | $51.73M | $52.40M | $53.73M | $58.72M | $57.77M | $55.24M |
| Intangibles | $34.50M | $35.25M | $36.00M | $0 | — | — | — | — |
| Total assets | $1.26B | $1.16B | $1.27B | $1.14B | $1.06B | $1.17B | $1.27B | $1.37B |
| Current liabilities | $95.26M | $90.08M | $110.16M | $98.35M | $90.15M | $91.06M | $91.88M | $102.21M |
| Total liabilities | $329.65M | $322.78M | $339.93M | $131.09M | $129.42M | $139.19M | $148.66M | $144.50M |
| Shareholders' equity | $926.39M | $835.18M | $926.10M | $1.01B | $926.20M | $1.03B | $1.12B | $1.23B |
| Shares outstanding | 160.26M | 159.76M | 158.66M | 156.18M | 146.63M | 145.69M | 145.25M | 144.22M |
| Cash flow statement | ||||||||
| Operating cash flow | -$117.44M | -$97.00M | -$131.20M | -$98.54M | -$107.30M | -$75.30M | -$131.47M | -$83.72M |
| Capital expenditure | $1.01M | $805,000 | $2.47M | $1.52M | -$1.38M | $4.28M | $5.08M | $5.09M |
| Free cash flow | -$118.45M | -$97.81M | -$133.67M | -$100.06M | -$105.92M | -$79.58M | -$136.55M | -$88.81M |
| Investing cash flow | $16.19M | -$104.08M | $94.46M | $20.77M | $57.83M | $157.94M | $18.75M | $172.21M |
| Financing cash flow | $2.59M | $14.98M | $219.04M | $192.13M | -$778,000 | $1.62M | -$3.76M | -$4.17M |
| Depreciation & amortization | $3.58M | $3.57M | $2.85M | $2.87M | $2.95M | $3.04M | $2.33M | $1.85M |
| Stock-based compensation | $22.86M | $22.91M | $23.09M | $23.95M | $25.14M | $25.39M | $25.16M | $25.08M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.